Determinants of antiviral effectiveness in influenza virus a subtype H5N1

Journal of Infectious Diseases

Volumn 206, Issue 9, 2012, Pages 1359-1366

  Chan, Paul K S ^a   Lee, Nelson ^a   Zaman, Mukhtiar ^c   Adisasmito, Wiku ^d   Coker, Richard ^e   Hanshaoworakul, Wanna ^g   Gasimov, Viktor ^h   Oner, Ahmet Faik ⁱ   Dogan, Nazim ^j   Tsang, Owen ^b   Phommasack, Bounlay ^k   Touch, Sok ^l   Bamgboye, Ebun ^m   Swenson, Anna ⁿ   Toovey, Stephen ^f   Dreyer, Nancy A ⁿ  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

^c KHYBER TEACHING HOSPITAL   (Pakistan)

^d UNIVERSITY OF INDONESIA   (Indonesia)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g MINISTRY OF PUBLIC HEALTH   (Thailand)

^h Azerbaijan Ministry of Health   (Azerbaijan)

ⁱ YUZUNCU YIL UNIVERSITY   (Turkey)

^j ATATURK UNIVERSITY   (Turkey)

^k Ministry of Health   (Laos)

^l Ministry of Health Cambodia   (Cambodia)

^m St Nicholas Hospital   (Nigeria)

ⁿ IQVIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; OSELTAMIVIR;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLADISTICS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; EARLY INTERVENTION; FATALITY; FEMALE; HOSPITAL ADMISSION; HUMAN; INFANT; INFECTION RISK; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MORTALITY; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY FAILURE; SURVIVAL RATE; SYMPTOM; TREATMENT OUTCOME; VIRAL CLADE; VIRUS SHEDDING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; RESPIRATORY INSUFFICIENCY; SECONDARY PREVENTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867489363     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis509     Document Type: Article

References (33)

1. World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2011. 10 October 2011. http://www.who.int/influenza/human-animal-interface/EN-GIP- 20111010CumulativeNumberH5N1cases.pdf. Accessed 15 December 2011.
2. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A(H5N1) Virus. Update on avian influenza A(H5N1) virus infection in humans. N Engl J Med 2008; 358:261-73.
3. Adisasmito W, Chan PKS, Lee N, et al. Effectiveness of antiviral treatment in human influenza H5N1 infections: Analysis from a global patient registry. J Infect Dis 2010; 202:1154-60.
4. Dreyer N, Starzyk K, Wilcock K, Toovey S. A global Registry for understanding clinical presentation, treatment outcomes and survival from human avian influenza. Bangkok, Thailand: BIOTEC, 2008:155.
5. World Health Organization. Continuing progress towards a unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses -full tree, January, 2009. March 2009. http://www.who. int/csr/disease/avian- influenza/guidelines/nomenclature/en/index.html. Accessed 28 September 2011.
6. World Health Organization. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines. 17 February 2011. http://www.who.int/csr/disease/avian-influenza/guide lines/h5n1virus/en/index. html. Accessed 28 September 2011.
7. Uyeki TM. Human infection with highly pathogenic avian influenza A(H5N1) virus: Review of clinical issues. Clin Infect Dis 2009; 49:279-90.
8. World Health Organization. Evolution of H5N1 avian Influenza viruses in Asia. Emerg Infect Dis 2005; 11:1515-21.
9. Puthavathana P, Sangsiriwut K, Korkusol A, et al. Avian influenza virus (H5N1) in human, Laos. Emerg Infect Dis 2009; 15:127-9.
10. Kitphati R, Pooruk P, Lerdsamran H, et al. Kinetics and longevity of antibody response to influenza A H5N1 virus infection in humans. Clin Vaccine Immunol 2009; 16:978-81.
11. Zaman M, Ashraf S, Dreyer N, Toovey S. An extended review of human infection with influenza H5N1 virus in North West Frontier Province (NWFP), Pakistan, in 2007. Emerg Infect Dis 2011; 17: 1056-9.
12. Le MTQ, Wertheim HFL, Nguyen HD, et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 in humans in Northern Vietnam. PLoS One 2008; 3: E3339.
13. Nguyen TD, Nguyen TV, Vijaykrishna D, et al. Multiple sublineages of influenza A virus (H5N1), Vietnam, 2005-2007. Emerg Infect Dis 2008; 14:632-6. (Pubitemid 351520866)
14. Le QM, Ito M, Muramoto Y, et al. Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans between 2003 and 2008 in northern Vietnam. J Gen Virol 2010; 91: 2485-90.
15. Janeway C Jr, Travers P, Walport M, Capra JD. Immunobiology: The immune system in health and disease. Fourth ed. London: Taylor & Francis Inc.; 1999.
16. Mahon BP. The rational design of vaccine adjuvants for mucosal and neonatal immunization. Curr Med Chem 2001; 8:1057-75. (Pubitemid 32633659)
17. Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis 2012; 55:26-32.
18. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A(H5N1) virus infection in humans. N Engl J Med 2008; 358:261-73.
19. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza a (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-7. (Pubitemid 44527358)
20. Chan PKS. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 2002; 34(Suppl 2):S58-64. (Pubitemid 34442210)
21. Update: WHO -confirmed human cases of avian influenza A(H5N1) infection, 25 November 2003-24 November 2006. Wkly Epidemiol Rec 2007; 82:41-8. http://www.who.int/wer/2007/wer8206.pdf. Accessed 15 December 2011.
22. Yuen KY, Chan PKS, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998; 351:467-71. (Pubitemid 28070092)
23. Liem NT, Tung CV, Hien ND, et al. Clinical features of human influenza A(H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis 2009; 48:1639-46.
24. Hurt AC, Lowther S, Middleton D, Barr IG. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral Res 2010; 87:361-6. Epub 2010 Jul 21.
25. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 2007; 73:228-31. Epub 2006 Nov 10. PubMed PMID: 17112602.
26. Earhart KC, Elsayed NM, Saad MD, et al. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Health 2009; 2:74-80. Epub 2009 May 27.
27. Boltz DA, Douangngeun b, Phommachanh P, et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol 2010; 91:949-59.
28. Adisasmito W, Chan PKS, Lee N, et al. Strengthening observational evidence for antiviral effectiveness in H5N1. J Infect Dis 2011; 204:810-11.
29. Dreyer NA, Toovey S, Adisasmito W, et al. Handling missing data in prospective registries. In: Abstract presented at Agency for Healthcare Research and Quality 3rd Symposium on Comparative Effectiveness Research Methods; 2011 Jun 6-7; Rockville, MD.
30. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
31. Brun-Buisson C, Richard JC, Mercat A, Thiébaut AC, Brochard L; REVA-SRLF A/H1N1v 2009 Registry Group. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183:1200-6.
32. Abdel-Ghafar AN, Chotpitayasunondh T, et al. Writing committee of the second world health organization consultation on clinical aspects of human infection with avian influenza A(H5N1) virus. Update on avian influenza A(H5N1) virus infection in humans. N Engl J Med 2008; 358:261-73.
33. Lee N, Hui DSC. Dexamethasone in community-acquired pneumonia. Lancet 2011; 378:979-80.